Term ends no later than Nov 3, 2032 · Medium confidence
20-year base term ends Apr 20, 2032
In force on USPTO's status record and by its fee record. A terminal disclaimer on file may shorten this term, possibly to a date already past; its reference document is unresolved, so the date above is an upper bound and no earlier date is guessed.
Held by Amgen Inc.
Filed Jul 3, 2018 as application 16/026,294 · Granted Feb 16, 2021
Base term plus 197 days of patent term adjustment (USPTO delay)
Today
2012
2032
Clock starts
Apr 20, 2012
Apr 20, 2012
Ends no later than
Nov 3, 2032
Nov 3, 2032
Granted
Feb 16, 2021
Feb 16, 2021
base term
patent term adjustment
fee events
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
197
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
Unresolved
Terminal disclaimer
On file, reference document not resolved, so the date above is an upper bound. We do not guess the cap.
1 of 2
Maintenance fees paid
Two maintenance fees can end this term early, the ones due 3.5 and 7.5 years from grant; the third one's grace period runs past the term end. This counts the ones the record shows paid.
11
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term runs 197 days past its 20-year base term on prosecution delay. A terminal disclaimer is on file with no resolved reference, so no cap is applied and none is guessed. 1 of 2 maintenance fees is paid so far. Confidence: Medium. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Apr 20, 2012, when application PCT/US2012/034535, the earliest non-provisional in its chain, was filed (this one was filed Jul 3, 2018) | Apr 20, 2032 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | +197 days, USPTO patent term adjustment record | Nov 3, 2032 | High confidence |
| Terminal disclaimer cap | Disclaimer on file (approved), reference document not resolved | no cap applied, and none guessed | Medium confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 1 of 2 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | no later than Nov 3, 2032 | Medium confidence |
This family
| Application PCT/US2012/034535 | PCT application no patent term | no patent term |
| US 10,092,706 | In force Dec 2033 | Dec 2033 |
| US D808,010 | In force Jan 2033 | Jan 2033 |
| US D819,201 | In force May 2033 | May 2033 |
| US D829,890 | In force Oct 2033 | Oct 2033 |
| US D898,908 | In force Oct 2035 | Oct 2035 |
| US 10,918,805 | this patent no later than Nov 2032 | no later than Nov 2032 |
| US 11,419,990 | In force Mar 2033 | Mar 2033 |
8 of 11 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Feb 14, 2019 Reel 48339, frame 896 | Johnston, Neal; Ganzitti, Gabriele; Ewing, Kenneth R. | Amgen Inc.; Flextronics Medical Sales and Marketing, Ltd. | Assignment of Assignor's Interest |
| Feb 14, 2019 Reel 48339, frame 928 | Flextronics Medical Sales and Marketing, Ltd. | Amgen Inc. | Assignment of Assignor's Interest |
| Feb 14, 2019 Reel 48340, frame 36 | Denzer, Michael; Swift, Robert W.; Krishna, Suhas | Amgen Inc. | Assignment of Assignor's Interest |
| Feb 14, 2019 reel/frame not recorded | Ganzitti, Gabriele; Ewing, Kenneth R.; Johnston, Neal | Amgen Inc. | Assignment of Assignor's Interest |
| Feb 14, 2019 reel/frame not recorded | Ganzitti, Gabriele; Ewing, Kenneth R.; Johnston, Neal | Flextronics Medical Sales and Marketing, Ltd. | Assignment of Assignor's Interest |
| Feb 18, 2019 Reel 48357, frame 573 | Johnston, Neal; Ganzitti, Gabriele; Ewing, Kenneth R. | Flextronics Medical Sales and Marketing, Ltd. | Corrective Assignment to Correct the Removal of Assignee Amgen Inc. Previously Recorded at Reel: 048339 Frame: 0896. Assignor(S) Hereby Confirms the Assignment. |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Nov 2032
Term ends no later than Nov 3, 2032. Maintenance fees still fall due before then
Note
A terminal disclaimer is on file and its reference is not resolved. No cap is applied and none is guessed
Note
The 197 days of patent term adjustment (USPTO delay) are read from the USPTO record, not recalculated by us
Open question
A terminal disclaimer is on file (approved) and its reference document is not resolved. A disclaimer would cap the term earlier than Nov 3, 2032. We will not guess the cap.
Citations
0
later US patents cite this one
That is below the median of utility patents granted in 2021 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
This computed term ends no later than the date shown; an unresolved terminal disclaimer may end it earlier. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.